^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19.t-haNK

    i
    Other names: CD19.t-haNK
    Associations

    News

    Trials
    Company:
    ImmunityBio
    Drug class:
    CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    9ms
    Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, ImmunityBio, Inc.
    New P1 trial • Combination therapy
    |
    Rituxan (rituximab) • CD19.t-haNK
    11ms
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    over1year
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Apr 2023 --> Sep 2023
    Trial initiation date • Combination therapy
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    almost2years
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Nov 2022 --> Mar 2023
    Trial initiation date • Combination therapy
    |
    CD19 (CD19 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    2years
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P1 trial • Combination therapy
    |
    CD19 (CD19 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    over2years
    CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. (PubMed, Cytotherapy)
    Expression of CCR7 receptor by off-the-shelf t-haNK cells improves their homing toward lymph node chemokines both in vitro and in vivo, resulting in superior tumor control.
    Preclinical • Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    CD19 expression • CCR7 expresion
    |
    CD19.t-haNK
    over3years
    QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, ImmunityBio, Inc. | N=18 --> 0 | Not yet recruiting --> Withdrawn
    Clinical • Enrollment change • Trial withdrawal
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    CD19.t-haNK